Belimumab in systemic lupus erythematosus: Experience in clinical practice settings in a regional hospital

Riancho‐Zarrabeitia, Leyre; Blanco, Ignacio; Santos-Gόmez, M.; Aurrecoechea, Elena

doi:10.1016/j.reumae.2018.02.005

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…treated with BEL Binda V 99 2020 case series 1/17 SoC 1 case of LN flare in a cohort of 17 LN pts. treated with BEL Riancho-Zarrabeitia L 106 2020 retrospective analysis 1/11 HCQ (all) MMF, AZA, CYC, LEF (several) 1 case of de novo LN in a cohort of 11 SLE pts. treated with BEL for musculoskeletal and/or cutaneous manifestations Hassan S 107 2020 prospective observational study 2/14 SoC study with secondary non-responders to RTX in SLE, details see Table 4 1 patient relapsed with LN class III during BEL treatment, another developed de novo LN class V; both were then treated with CYC Parodis I 102 2020 prospective observational study 6/66 de novo 2/29 flare SoC 6 out of 66 SLE pts.…”

Section: The Product Of Interestmentioning

confidence: 99%

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis

Plüß

Piantoni

Tampe

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

In recent years, advances in the treatment and management of patients with systemic lupus erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus nephritis (LN) still represents a major life-threatening complication of the disease. Belimumab (BEL), a fully human monoclonal IgG1λ antibody neutralizing soluble B cell activating factor, was approved more than ten years ago as add-on therapy in adults and pediatric patients with a highly active, autoantibody-positive disease despite standard of care (SoC). Recently, the superiority of the addition of BEL to SoC was also demonstrated in LN. In this review, we provide a comprehensive overview of the study landscape, available therapeutic options for SLE (focusing on BEL in renal and non-renal SLE), and new perspectives in the treatment field of this disease. A personalized treatment approach will likely become available with the advent of novel therapeutic agents for SLE and LN.

show abstract